Scout Investments Inc. decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 55.8% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 138,545 shares of the company’s stock after selling 174,657 shares during the period. Scout Investments Inc. owned 0.11% of Ionis Pharmaceuticals worth $7,048,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of IONS. Teachers Advisors LLC increased its holdings in shares of Ionis Pharmaceuticals by 14.7% during the 4th quarter. Teachers Advisors LLC now owns 123,810 shares of the company’s stock valued at $5,922,000 after acquiring an additional 15,904 shares during the last quarter. Capstone Asset Management Co. increased its holdings in shares of Ionis Pharmaceuticals by 10.3% during the 1st quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock valued at $207,000 after acquiring an additional 480 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of Ionis Pharmaceuticals by 72.4% during the 1st quarter. Canada Pension Plan Investment Board now owns 111,410 shares of the company’s stock valued at $4,479,000 after acquiring an additional 46,800 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Ionis Pharmaceuticals by 186.9% during the 1st quarter. Advisors Asset Management Inc. now owns 6,542 shares of the company’s stock valued at $263,000 after acquiring an additional 4,262 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Ionis Pharmaceuticals by 20.4% during the 1st quarter. American Century Companies Inc. now owns 861,957 shares of the company’s stock valued at $34,651,000 after acquiring an additional 145,850 shares during the last quarter. 89.33% of the stock is currently owned by institutional investors and hedge funds.
In other news, SVP C Frank Bennett sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the transaction, the senior vice president now owns 25,041 shares of the company’s stock, valued at $1,484,680.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Stanley T. Crooke sold 16,500 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $52.10, for a total value of $859,650.00. Following the completion of the transaction, the chairman now directly owns 51,476 shares in the company, valued at approximately $2,681,899.60. The disclosure for this sale can be found here. Insiders sold 55,309 shares of company stock worth $2,997,692 in the last ninety days. 1.86% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://ledgergazette.com/2017/09/17/scout-investments-inc-reduces-stake-in-ionis-pharmaceuticals-inc-ions.html.
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at 59.23 on Friday. The firm has a 50 day moving average price of $51.34 and a 200-day moving average price of $48.10. Ionis Pharmaceuticals, Inc. has a 12 month low of $24.58 and a 12 month high of $60.01. The company has a market cap of $7.37 billion, a P/E ratio of 284.76 and a beta of 3.13.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. During the same period in the previous year, the company posted ($0.47) EPS. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% compared to the same quarter last year. Analysts anticipate that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.
A number of research analysts have recently commented on the company. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the company a “hold” rating in a report on Wednesday, August 9th. TheStreet raised Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Wednesday, July 26th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Evercore ISI assumed coverage on Ionis Pharmaceuticals in a research note on Wednesday, August 16th. They set an “outperform” rating and a $65.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $49.31.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.